Szablowska-Gadomska Ilona, Sypecka Joanna, Zayat Valery, Podobinska Martyna, Pastwinska Anna, Pienkowska-Grela Barbara, Buzanska Leonora
NeuroRepair Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Acta Neurobiol Exp (Wars). 2012;72(4):337-50. doi: 10.55782/ane-2012-1906.
Standardization of methods for obtaining iPS cells from the human somatic cells and then their successful differentiation are important in the context of their possible application in personalized cell therapy and the development of toxicological and pharmacological tests. In the present study, the influence of the small molecules representing epigenetic modulators (histone deacetylase inhibitor Trichostatin A and DNA methyltransferase inhibitor RG-108) on the process of reverting neural progenitors from HUCB-NSC (Human Umbilical Cord Blood Neural Stem Cell) line to the pluripotent state was tested. The experiments were conducted in low oxygen tension, in three different experimental layouts: (1) in the presence of reprogramming/recombinant polyarginine-tailed proteins; (2) with recombinant proteins and small molecules; (3) only in the presence of small molecules. We wanted to find out, whether it will be possible to induce pluripotent state of neural stem cells only by epigenetic modulators. Our results revealed that the inhibitors of DNA methylation and histone deacetylation used along with 5 percent oxygen tension can only transiently induce or elevate some pluripotency genes in neural progenitors with different pattern, but were not sufficient for stable reprogramming. The iPS cells from neural progenitor cells of HUCBNSC were obtained only when TSA, RG-108 and reprogramming proteins have been applied simultaneously. These cells were tested for the expression of the selected pluripotency genes and in functional assays to prove their pluripotency stage. The obtained data show that the small molecules in conjunction with reprogramming factors are the potent tools in cell reprogramming.
从人类体细胞中获取诱导多能干细胞(iPS细胞)的方法标准化以及随后它们的成功分化,在其可能应用于个性化细胞治疗以及毒理学和药理学测试开发的背景下非常重要。在本研究中,测试了代表表观遗传调节剂的小分子(组蛋白去乙酰化酶抑制剂曲古抑菌素A和DNA甲基转移酶抑制剂RG - 108)对将人脐带血神经干细胞(HUCB - NSC)系的神经祖细胞重编程为多能状态过程的影响。实验在低氧张力下进行,采用三种不同的实验布局:(1)在重编程/重组聚精氨酸尾蛋白存在的情况下;(2)使用重组蛋白和小分子;(3)仅在小分子存在的情况下。我们想弄清楚,是否仅通过表观遗传调节剂就能诱导神经干细胞进入多能状态。我们的结果表明,与5%氧张力一起使用的DNA甲基化和组蛋白去乙酰化抑制剂只能短暂地以不同模式诱导或提高神经祖细胞中的一些多能性基因,但不足以实现稳定的重编程。仅当同时应用曲古抑菌素A、RG - 108和重编程蛋白时,才能从HUCBNSC的神经祖细胞中获得iPS细胞。对这些细胞进行了所选多能性基因的表达测试,并进行了功能分析以证明其多能阶段。获得的数据表明,小分子与重编程因子结合是细胞重编程的有效工具。